Showing results (41-50 of 108) with videos related to
Sort By:
Pageof 11
Journal of Clinical Microbiology|October 6, 2006
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methodsM A Pfaller, L Boyken, R J Hollis, et al.Journal of Clinical Microbiology|November 8, 2005
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleM A Pfaller, L Boyken, R J Hollis, et al.Journal of Clinical Microbiology|May 8, 2003
Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazoleM A Pfaller, D J Diekema, L Boyken, et al.Journal of Clinical Microbiology|May 8, 2003
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic locationM A Pfaller, S A Messer, L Boyken, et al.Antimicrobial Agents and Chemotherapy|October 18, 2002
In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methodsM A Pfaller, S A Messer, L Boyken, et al.Journal of Clinical Microbiology|October 7, 2005
Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance programM A Pfaller, L Boyken, S A Messer, et al.Journal of Clinical Microbiology|August 6, 2005
In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsM A Pfaller, L Boyken, R J Hollis, et al.Antimicrobial Agents and Chemotherapy|September 19, 2000
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformansT Yamazumi, M A Pfaller, S A Messer, et al.Diagnostic Microbiology and Infectious Disease|November 1, 1995
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patientsF Barchiesi, R J Hollis, S A Messer, et al.Journal of Clinical Microbiology|December 21, 2007
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance programM A Pfaller, S A Messer, L Boyken, et al.Pageof 11